Buy or sell Kronos Bio stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Kronos Bio Stock

Kronos Bio is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets.

About Kronos Bio Stock

Kronos Bio is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. It develops therapies that modulate historically undruggable targets. The company leverages deep capabilities in high-throughput small-molecule microarrays (SMM), targeted protein degradation, and cancer biology in order to identify potent and selective compounds against transcription factors and other central drivers of oncogenic signaling. . In 2017, Angela Koehler, Christopher Wilfong​, and Joshua A. Kazam established Kronos Bio in San Mateo California.

Funding History

June 2018$18.0M
July 2019$105M

Management

Vice President, Program Management

Christopher Lee

Vice President, Pharmacology

Douglas C. Saffran

President & Chief Executive Officer

Norbert Bischofberger

Chief Operating Officer and Founder

Christopher Wilfong

Vice President, Clinical Operations

Zung To

Vice President, Biology

Charles Lin

Vice President, Chemistry

Wes Trotter

Scientific Founder

Angela Koehler

Chief Medical Officer & Executive Vice President, Clinical Development

Jorge DiMartino

Chief Business Officer

Philip P. Gutry

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Kronos Bio or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 140K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo